Blockade of K+ channels in insulin-secreting cells by the 'potassium channel opener' SDZ PCO 400.
Harding
E A
EA
Department of Biomedical Science, The University, Western Bank, Sheffield.
Finch
A
A
Dunne
M J
MJ
D000818:Animals; D001578:Benzopyrans / Q000494:pharmacology*; D002462:Cell Membrane / Q000187:drug effects / Q000502:physiology; D003517:Cyclopentanes / Q000494:pharmacology*; D003981:Diazoxide / Q000494:pharmacology; D066298:In Vitro Techniques; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D008564:Membrane Potentials / Q000187:drug effects; D010646:Phentolamine / Q000494:pharmacology; D026902:Potassium Channel Blockers; D015221:Potassium Channels / Q000502:physiology; D051381:Rats; D014044:Tolbutamide / Q000494:pharmacology
D001578:Benzopyrans; D003517:Cyclopentanes; D007328:Insulin; D026902:Potassium Channel Blockers; D015221:Potassium Channels; C073091:SDZ PCO 400; D014044:Tolbutamide; D003981:Diazoxide; D010646:Phentolamine